Monitoring the progression of metastatic breast cancer on nanoporous silica chips.
Monitoring the progression of metastatic breast cancer on nanoporous silica chips.
复制标题
DOI：
10.1098/rsta.2011.0444
复制
发表时间：
2012-05-28
期刊：
影响因子：
--
通讯作者：
Hu Y
中科院分区：
文献类型：
--
作者：
Fan J;Deng X;Gallagher JW;Huang H;Huang Y;Wen J;Ferrari M;Shen H;Hu Y
2010年，乳腺癌占女性癌症患者死亡总数的15%。虽然在治疗早期乳腺癌患者方面取得了显著进展，但除了常规化疗干预外，仍然没有针对晚期转移性乳腺癌的有效治疗。在晚期癌症的有效治疗出现之前，识别用于早期检测肿瘤转移的生物标志物仍然是成功管理乳腺癌治疗的关键。我们的研究集中在血清蛋白的低分子量（LMW）区域及其包含的信息，用于识别可以反映所有组织正在进行的生理状态的生物标志物。由于收获LMW物质的技术困难，研究这些蛋白质/肽迄今为止一直具有挑战性。在我们的研究中，我们最近开发了基于纳米多孔芯片的技术，以将血清中的小蛋白质/肽与大蛋白质分离。我们使用具有高度周期性纳米结构和均匀孔径分布的纳米多孔二氧化硅芯片，从具有MDA-MB-231人乳腺癌肺转移的裸鼠血清中分离LMW蛋白和肽。通过基质辅助激光解吸/电离飞行时间质谱和生物统计学分析，我们能够识别癌症发展不同阶段特有的蛋白质特征。本研究报告的方法和结果具有发现蛋白质组生物标志物的巨大潜力，这些生物标志物可能显着增强针对转移性乳腺癌的个性化药物。
Breast cancer accounted for 15 per cent of total cancer deaths in female patients in 2010. Although significant progress has been made in treating early-stage breast cancer patients, there is still no effective therapy targeting late-stage metastatic breast cancers except for the conventional chemotherapy interventions. Until effective therapy for later-stage cancers emerges, the identification of biomarkers for the early detection of tumour metastasis continues to hold the key to successful management of breast cancer therapy. Our study concentrated on the low molecular weight (LMW) region of the serum protein and the information it contains for identifying biomarkers that could reflect the ongoing physiological state of all tissues. Owing to technical difficulties in harvesting LMW species, studying these proteins/peptides has been challenging until now. In our study, we have recently developed nanoporous chip-based technologies to separate small proteins/peptides from the large proteins in serum. We used nanoporous silica chips, with a highly periodic nanostructure and uniform pore size distribution, to isolate LMW proteins and peptides from the serum of nude mice with MDA-MB-231 human breast cancer lung metastasis. By matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and biostatistical analysis, we were able to identify protein signatures unique to different stages of cancer development. The approach and results reported in this study possess a significant potential for the discovery of proteomic biomarkers that may significantly enhance personalized medicine targeted at metastatic breast cancer.
登录
查看更多内容
DOI：
10.1111/j.1749-6632.2010.05779.x
发表时间：
2010-01-01
期刊：
TOWARD PERSONALIZED MEDICINE FOR CANCER
影响因子：
--
作者：
Riethdorf, Sabine;Pantel, Klaus
通讯作者：
Pantel, Klaus
影响因子：
9.6
作者：
Hu Ye;Peng Yang;Brousseau, Louis;Bouamrani, Ali;Liu XueWu;Ferrari, Mauro
通讯作者：
Ferrari, Mauro
影响因子：
2.4
作者：
Gao, Dongwei;Du, Jiajun;Liu, Qi
通讯作者：
Liu, Qi
影响因子：
6.7
作者：
Hu Y;Peng Y;Lin K;Shen H;Brousseau LC 3rd;Sakamoto J;Sun T;Ferrari M
通讯作者：
Ferrari M
影响因子：
4
作者：
Feng, Yongdong;Wen, Jianguo;Chang, Chung-Che
通讯作者：
Chang, Chung-Che